- Trials with a EudraCT protocol (68)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
68 result(s) found for: Cytarabine.
Displaying page 1 of 4.
EudraCT Number: 2015-004896-60 | Sponsor Protocol Number: LUMC2015-02 | Start Date*: 2015-11-26 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk | ||
Medical condition: Acute myeloid leukemia and high risk myelodysplasia | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002345-39 | Sponsor Protocol Number: Göteborg University | Start Date*: 2006-02-16 |
Sponsor Name:NOPHO NHL-group | ||
Full Title: B-NHL BFM 04 | ||
Medical condition: B-cell lymphoma or B-ALL in children up to 18 years of age | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003025-28 | Sponsor Protocol Number: TUD-RELAX1-070 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Technische Universität Dresden | |||||||||||||
Full Title: Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax | |||||||||||||
Medical condition: Patients 18-75 years with acute myeloid leukaemia (AML) at first or second relapse after intensive chemotherapy including allogeneic stem cell transplantation or primary refractory to standard indu... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000344-42 | Sponsor Protocol Number: AG-221-AML-004 | Start Date*: 2016-01-21 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemi... | ||||||||||||||||||
Medical condition: Treatment of subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase 2 (IDH2) mut... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed) BE (Completed) AT (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-010951-28 | Sponsor Protocol Number: CLTR0308-205 | Start Date*: 2009-09-30 | |||||||||||
Sponsor Name:Celator Pharmaceuticals, Inc | |||||||||||||
Full Title: Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients ≤ 60 years old with AML in first rela... | |||||||||||||
Medical condition: Acute myeloid leukemia recurrent (Acute Myeloid Leukemia in First Relapse Following an Initial CR >1 Month Duration). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004421-24 | Sponsor Protocol Number: LUMC2012-02 | Start Date*: 2014-04-14 |
Sponsor Name:Leiden Universtity Medical Center | ||
Full Title: Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation (TCD FLAMSA-RIC alloSCT) in elderly acute myeloid leukemia and high risk myelo... | ||
Medical condition: acute myeloid leukemia and high risk myelodysplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006084-23 | Sponsor Protocol Number: P060239 | Start Date*: 2007-05-28 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude multicentrique, randomisée , de phase II évaluant l'association méthotrexate et témozolomide (MT) à l'association méthotrexate, procarbazine, vincristine et cytarabine (MPV-A) dans le traitem... | |||||||||||||
Medical condition: Lymphome Primitif du Système Nerveux Central (LPSNC) chez le sujet âgé | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002885-34 | Sponsor Protocol Number: CHIP-AML22/Master | Start Date*: 2023-03-17 |
Sponsor Name:Princess Máxima Center | ||
Full Title: CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium | ||
Medical condition: Acute Myeloid Leukemia | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001976-12 | Sponsor Protocol Number: FLAG-QUIDA | Start Date*: 2019-09-12 | |||||||||||
Sponsor Name:Fundación Pethema | |||||||||||||
Full Title: A multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and the FLAG-IDA chemotherapy regimen in first relapsed/refract... | |||||||||||||
Medical condition: relapsed/refractory acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002141-37 | Sponsor Protocol Number: HOVON 80 NHL | Start Date*: 2006-09-28 | |||||||||||
Sponsor Name:HOVON foundation | |||||||||||||
Full Title: Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-ce... | |||||||||||||
Medical condition: relapsed B cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000406-28 | Sponsor Protocol Number: VEN-A-QUI | Start Date*: 2020-09-18 | |||||||||||
Sponsor Name:Fundación Pethema | |||||||||||||
Full Title: A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnos... | |||||||||||||
Medical condition: Newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003248-26 | Sponsor Protocol Number: TUD-VINC01-080 | Start Date*: 2023-06-01 | |||||||||||
Sponsor Name:Technische Universität Dresden | |||||||||||||
Full Title: Venetoclax plus Azacitidine versus Standard intensive Chemotherapy for Patients with newly diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations eligible for intensive Treatment (VINCENT) | |||||||||||||
Medical condition: Patients 18-70 years eligible for intensive therapy with newly diagnosed acute myeloid leukemia (AML) harboring an NPM1 mutation and no activating FLT3 mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006295-11 | Sponsor Protocol Number: ICOG-2007 | Start Date*: 2008-04-07 | |||||||||||
Sponsor Name:Instituto de Investigación del Hospital de la Santa Creu i Sant Pau | |||||||||||||
Full Title: TREATMENT OF PRIMARY ACUTE MYELOID LEUKEMIA WITH THE COMBINATION OF IDARUBICIN, CYTARABINE AND GEMTUZUMAB OZOGAMYCIN (MYLOTARG) ASSOCIATED OR NOT TO G-CSF PRIMING: PROSPECTIVE STUDY OF EFFICACY AND... | |||||||||||||
Medical condition: Leucemia Mieloide Aguda Primaria "de novo" | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004517-17 | Sponsor Protocol Number: CGX-635-AML-204 | Start Date*: 2006-11-29 | |||||||||||
Sponsor Name:Stragen France | |||||||||||||
Full Title: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Refractory or Relapsed Acute Myeloid Leukemia (AML) | |||||||||||||
Medical condition: Acute Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000334-19 | Sponsor Protocol Number: 702 | Start Date*: 2012-08-09 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE | |||||||||||||
Full Title: Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML) | |||||||||||||
Medical condition: Untreated patients aged 60> years with Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000470-21 | Sponsor Protocol Number: JNJ-30979754 | Start Date*: 2008-08-04 | |||||||||||
Sponsor Name:Groupe Francophone des Myélodysplasies | |||||||||||||
Full Title: A Phase II study of Decitabine in patients with Chronic Myelomonocytic Leukemia | |||||||||||||
Medical condition: Chronic Myelomonocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001647-30 | Sponsor Protocol Number: ESPHALL | Start Date*: 2004-04-28 | |||||||||||
Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA | |||||||||||||
Full Title: An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) | |||||||||||||
Medical condition: Children and adolescents aged 1-17 years at diagnosis, with Ph+ALL | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000354-25 | Sponsor Protocol Number: 2.1 | Start Date*: 2021-11-11 | |||||||||||||||||||||
Sponsor Name:FINBA | |||||||||||||||||||||||
Full Title: A multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients: efficacy and microbiologic safety. | |||||||||||||||||||||||
Medical condition: Post-chemotherapy neutropenia with high risk of developing infection in patients with acute leukemia undergoing induction, autologous or allogeneic hematopoietic stem cell transplantation. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004453-71 | Sponsor Protocol Number: AMLSG31-19 | Start Date*: 2022-02-01 |
Sponsor Name:University Hospital Ulm | ||
Full Title: A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrom... | ||
Medical condition: AML or MDS-EB2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001051-32 | Sponsor Protocol Number: 2102-HEM-101 | Start Date*: 2019-03-14 | |||||||||||||||||||||
Sponsor Name:Forma Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A Phase 1/2, Multicenter, Open-label Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an... | |||||||||||||||||||||||
Medical condition: Relapsed/refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
